

## Erratum to: Recording of hormone therapy and breast density in breast screening programs: summary and recommendations of the International Cancer Screening Network

Brian Cox · Rachel Ballard-Barbash · Mireille Broeders · Emily Dowling · Nea Malila · Rene Shumak · Stephen Taplin · Diana Buist · Diana Miglioretti

Published online: 15 June 2010  
© Springer Science+Business Media, LLC. 2010

### Erratum to: Breast Cancer Res Treat DOI 10.1007/s10549-010-0893-0

Authors regret to inform that, due to an unfortunate oversight, some data from the Swiss breast screening programme was omitted. The second and third sentences of the second paragraph of the Results should read.

Of the 29 countries approached, 8 programs recorded the use of prescribed HT at each screening episode (Table 1). Five of the eight also sought information about ever use of HT with four of the five, and one other, recording whether combined HT or progestin alone was prescribed.

The corrected Tables 1 and 2 are given as follows.

---

The online version of the original article can be found under doi:[10.1007/s10549-010-0893-0](https://doi.org/10.1007/s10549-010-0893-0).

---

B. Cox (✉)  
Hugh Adam Cancer Epidemiology Unit, Department of Preventive and Social Medicine, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand  
e-mail: [brian.cox@otago.ac.nz](mailto:brian.cox@otago.ac.nz)

R. Ballard-Barbash · E. Dowling · S. Taplin  
Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD 20892, USA

M. Broeders  
Department of Epidemiology, Biostatistics and Health Technology Assessment, Radboud University Nijmegen Medical Centre, Nijmegen 6500 HB, The Netherlands

N. Malila  
Mass Screening Registry, Finnish Cancer Registry, Helsinki 00130, Finland

N. Malila  
Tampere School of Public Health, University of Tampere, Tampere, Finland

R. Shumak  
Ontario Breast Screening Program, Cancer Care Ontario, Toronto, ON MN 6G9, Canada

D. Buist · D. Miglioretti  
Group Health Research Institute, Seattle, WA 98101, USA

**Table 1** Self-reported information on hormone therapy use in breast cancer screening programs: results from the International Cancer Screening Network

Country	At current screen HT use recorded	Current use of HRT	Ever HT use	Combined HT and progestin alone recorded separately	Age started	Duration in years	Linkage possible	Menopausal state recorded at screen
Australia	Yes	Yes					Yes	
Canada	Yes	Yes	Yes	Yes	No	No	Yes	Yes <sup>a</sup>
Denmark	Yes	Yes					Yes	
Finland	Yes	Yes	Yes	Yes			Yes	
Israel	Yes	Yes	Yes		Yes			Yes
New Zealand	No	No	No	No	No	No	Yes	No
Norway	Yes	Yes	Yes	Yes	Yes		Yes	
Switzerland	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
United States <sup>b</sup>	Yes	Yes	Some women	Yes <sup>b</sup>	Some women	Some women	Yes <sup>c</sup>	Yes <sup>d</sup>

<sup>a</sup> Only at first screen

<sup>b</sup> The US does not have a national screening program. Data were derived from the Breast Cancer Screening Consortium and only some registries collect the type of HT

<sup>c</sup> One center only

<sup>d</sup> Varies by program site

**Table 2** Recording of mammographic breast density (BD) in breast cancer screening programs: results from the International Cancer Screening Network

Country	BD collected at screen	Only at first screen	Measure used	Available by age group	Moving to full-field digital (FFD)	Has FFD changed way BD is measured	Computerized radiography (CR) used	Has CR changed way BD measured
Australia	No				Some women		Some women	
Denmark	Yes		Fatty or mixed	Yes	All women since 2007	No	Not used	
Canada	Yes	No			Some women	No	Some women	No
Finland	Yes <sup>a</sup>	No			Some women		Some women	
Germany	Yes				Some women		Some women	
Israel	Yes		4 descriptive categories		Some women		Some women	
Japan	No				Some women		Some women	
New Zealand	No				Some women		Some women	
Norway	No <sup>b</sup>		<30%, 30–70%, >70%	Yes	Some women		Not used	
Switzerland	Yes	No	4 descriptive categories	Yes	Some women	No		
UK	No				Some women		Some women	
United States <sup>c</sup>	Yes <sup>d</sup>	No	BI-RADS, MRS, Wolfe, dichotomous, other unnamed 4 category systems, continuous	Yes	Some women since 2001	No	Some women	
Czech Republic	Yes	No	Tabar classification	Yes	Some women		Some women	

<sup>a</sup> Historical data only and used Wolfe's classification

<sup>b</sup> Only recorded for women who were recalled

<sup>c</sup> The US does not have a national screening program. Data were derived from the Breast Cancer Screening Consortium

<sup>d</sup> BI-RADS is the majority, Wolfe no longer used 2000 forward, dichotomous no longer used 1999 forward